The Life Sciences Report Releases 2015 Small-Cap Biotech Watchlist Update

PETALUMA, CA--(Marketwired - May 15, 2015) - Streetwise Reports/The Life Sciences Report released its quarterly update to the 2015 Small-Cap Biotech Watchlist today. Analysts comments include updates on milestones for Can-Fite BioPharma Ltd. (NYSE MKT: CANF) and Sunesis Pharmaceuticals (NASDAQ: SNSS). The Watchlist is comprised of companies a panel assembled at the Biotech Showcase in January believed should see significant gains in 2015.

This marks the third year Streetwise Reports has tracked a basket of analyst-selected companies in real time throughout the year. "Our publications specialize in sharing insights from top experts in each sector; this adds the dynamic element of a live, graphic way to watch those ideas play out over time," explained Publisher Jim Patrick.

Panelists Reni Benjamin, head of equity research at H.C. Wainwright & Co.; Joe Pantginis, head of biotechnology research at Roth Capital Partners; and George Zavoico, managing director of equity research at MLV & Co, reflected on how the stocks they picked have performed and what they will be looking for in the coming months.

Readers can subscribe to The Life Sciences Report for free to get updates on the Watchlist and future interviews.

Streetwise Reports publishes The Life Sciences Report, in addition to The Gold Report and The Energy Report. These reports feature interviews with experts talking about macro-trends in and specific investing ideas in those sectors. Streetwise interviews are syndicated to major retail and institutional investing sites.

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development company with a platform technology that addresses multibillion dollar markets in the treatment of cancer, inflammatory and other diseases. The company completed its Phase 2/3 trials for psoriasis and is in Phase 2 trials for liver cancer. Study design for a Phase 3 trial in rheumatoid arthritis has been completed. Can-Fite has been granted orphan drug designation by the U.S. FDA for its liver cancer drug, which is approved for compassionate use by Israel's Ministry of Health.

Sunesis Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.